Valneva SE Sponsored ADR (NASDAQ:VALN - Get Free Report)'s stock price gapped up prior to trading on Thursday . The stock had previously closed at $7.32, but opened at $7.76. Valneva shares last traded at $8.06, with a volume of 281,588 shares trading hands.
Wall Street Analysts Forecast Growth
A number of brokerages have issued reports on VALN. HC Wainwright restated a "buy" rating and issued a $17.00 price objective on shares of Valneva in a research note on Tuesday, April 15th. Guggenheim reduced their price objective on Valneva from $15.00 to $14.00 and set a "buy" rating for the company in a research note on Thursday, May 8th.
Get Our Latest Report on VALN
Valneva Price Performance
The company has a debt-to-equity ratio of 0.92, a quick ratio of 2.12 and a current ratio of 2.70. The company has a market cap of $658.26 million, a P/E ratio of -6.50 and a beta of 1.74. The firm has a 50 day moving average price of $6.11 and a two-hundred day moving average price of $6.29.
Valneva (NASDAQ:VALN - Get Free Report) last issued its earnings results on Wednesday, May 7th. The company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.40) by $0.27. Valneva had a negative return on equity of 43.05% and a negative net margin of 43.08%. The business had revenue of $51.79 million during the quarter, compared to the consensus estimate of $41.80 million. On average, analysts predict that Valneva SE Sponsored ADR will post 0.13 EPS for the current fiscal year.
Institutional Trading of Valneva
An institutional investor recently raised its position in Valneva stock. Wells Fargo & Company MN lifted its holdings in Valneva SE Sponsored ADR (NASDAQ:VALN - Free Report) by 14.3% in the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 246,766 shares of the company's stock after acquiring an additional 30,859 shares during the quarter. Wells Fargo & Company MN owned 0.30% of Valneva worth $1,079,000 at the end of the most recent quarter. 11.39% of the stock is owned by hedge funds and other institutional investors.
Valneva Company Profile
(
Get Free Report)
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Valneva, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Valneva wasn't on the list.
While Valneva currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
